164 related articles for article (PubMed ID: 35876124)
1. Health utilities in Chinese patients with coronary heart disease and impaired glucose tolerance (ACE): A longitudinal analysis of a randomized, double-blind, placebo-controlled trial.
Leal J; Becker F; Lim LL; Holman RR; Gray AM
J Diabetes; 2022 Jul; 14(7):455-464. PubMed ID: 35876124
[TBL] [Abstract][Full Text] [Related]
2. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
[TBL] [Abstract][Full Text] [Related]
3. Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial.
Wamil M; McMurray JJV; Scott CAB; Coleman RL; Sun Y; Standl E; Rydén L; Holman RR
Diabetes Res Clin Pract; 2020 Dec; 170():108488. PubMed ID: 33035598
[TBL] [Abstract][Full Text] [Related]
4. Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial.
Gerstein HC; Coleman RL; Scott CAB; Xu S; Tuomilehto J; Rydén L; Holman RR;
Diabetes Care; 2020 Sep; 43(9):2242-2247. PubMed ID: 32641379
[TBL] [Abstract][Full Text] [Related]
5. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
Moelands SV; Lucassen PL; Akkermans RP; De Grauw WJ; Van de Laar FA
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD005061. PubMed ID: 30592787
[TBL] [Abstract][Full Text] [Related]
6. Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial.
Morrow LM; Becker F; Coleman RL; Gerstein HC; Rydén L; Schöder S; Gray AM; Leal J; Holman RR;
J Diabetes; 2024 Feb; 16(2):e13473. PubMed ID: 37915263
[TBL] [Abstract][Full Text] [Related]
7. Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).
Lewis EF; Li Y; Pfeffer MA; Solomon SD; Weinfurt KP; Velazquez EJ; Califf RM; Rouleau JL; Kober L; White HD; Schulman KA; Reed SD
JACC Heart Fail; 2014 Apr; 2(2):159-65. PubMed ID: 24720924
[TBL] [Abstract][Full Text] [Related]
8. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
[TBL] [Abstract][Full Text] [Related]
9. Tongxinluo capsule as supplementation and cardiovascular endpoint events in patients with coronary heart disease: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials.
Lv J; Liu S; Guo S; Gao J; Song Q; Cui X
J Ethnopharmacol; 2022 May; 289():115033. PubMed ID: 35091010
[TBL] [Abstract][Full Text] [Related]
10. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial.
Chiasson JL
Endocr Pract; 2006; 12 Suppl 1():25-30. PubMed ID: 16627376
[TBL] [Abstract][Full Text] [Related]
11. Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE Study.
Hayes A; Arima H; Woodward M; Chalmers J; Poulter N; Hamet P; Clarke P
Value Health; 2016 Jan; 19(1):36-41. PubMed ID: 26797234
[TBL] [Abstract][Full Text] [Related]
12. Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance.
Xu S; Scott CAB; Coleman RL; Tuomilehto J; Holman RR
J Diabetes; 2021 Oct; 13(10):817-826. PubMed ID: 33665904
[TBL] [Abstract][Full Text] [Related]
13. Prospective utility study of patients with multiple cardiovascular events.
Pockett RD; McEwan P; Ray J; Tran I; Shutler S; Martin S; Yousef Z; Bakhai A
J Med Econ; 2018 Jun; 21(6):616-621. PubMed ID: 29557218
[TBL] [Abstract][Full Text] [Related]
14. Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: A one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease.
Koyasu M; Ishii H; Watarai M; Takemoto K; Inden Y; Takeshita K; Amano T; Yoshikawa D; Matsubara T; Murohara T
Clin Ther; 2010 Aug; 32(9):1610-7. PubMed ID: 20974318
[TBL] [Abstract][Full Text] [Related]
15. Sex differences in health-related quality of life trajectories following myocardial infarction: national longitudinal cohort study.
Dondo TB; Munyombwe T; Hall M; Hurdus B; Soloveva A; Oliver G; Aktaa S; West RM; Hall AS; Gale CP
BMJ Open; 2022 Nov; 12(11):e062508. PubMed ID: 36351712
[TBL] [Abstract][Full Text] [Related]
16. Effect of acarbose on cardiovascular events and new-onset diabetes in patients with coronary heart disease and impaired glucose tolerance.
Wei Y; Xu W
Future Cardiol; 2019 Mar; 15(2):127-133. PubMed ID: 30793928
[TBL] [Abstract][Full Text] [Related]
17. Plasma BNP Levels and Diuretics Use as Predictors of Cardiovascular Events in Patients with Myocardial Infarction and Impaired Glucose Tolerance.
Shindo K; Fukuda H; Hitsumoto T; Ito S; Kim J; Washio T; Kitakaze M
Cardiovasc Drugs Ther; 2020 Feb; 34(1):79-88. PubMed ID: 32076931
[TBL] [Abstract][Full Text] [Related]
18. Exercise-based cardiac rehabilitation for coronary heart disease.
Anderson L; Thompson DR; Oldridge N; Zwisler AD; Rees K; Martin N; Taylor RS
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD001800. PubMed ID: 26730878
[TBL] [Abstract][Full Text] [Related]
19. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
Diabetologia; 2004 Jun; 47(6):969-75; discussion 976-7. PubMed ID: 15164169
[TBL] [Abstract][Full Text] [Related]
20. Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?
Asakura M; Kim J; Asanuma H; Hamasaki T; Tsukahara K; Higashino Y; Ishikawa T; Nakama Y; Koba S; Maruyama Y; Tsujimoto M; Himeno H; Ohkusa T; Fujino S; Shimizu M; Endo T; Yoda S; Muroya T; Murohara T; Ohte N; Suzuki H; Kohno T; Fukui K; Shiono T; Takase H; Uzui H; Nagai Y; Hashimoto Y; Ikeda S; Mizuno S; Tamita K; Fujita M; Satake K; Kinoshita Y; Nunohiro T; Sakagami S; Higaki J; Morii I; Sawada R; Hiasa Y; Shigemasa T; Nakahama M; Sata M; Doi O; Ueda T; Yamada T; Yamanouchi T; Yamaguchi H; Morita Y; Hayashi H; Kitakaze M;
Cardiovasc Drugs Ther; 2017 Aug; 31(4):401-411. PubMed ID: 28779371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
